粪肠球菌中与喹诺酮耐药性相关的DNA回旋酶GyrA亚基和DNA拓扑异构酶IV的ParC亚基的改变。
Alterations in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV associated with quinolone resistance in Enterococcus faecalis.
作者信息
Kanematsu E, Deguchi T, Yasuda M, Kawamura T, Nishino Y, Kawada Y
机构信息
Department of Urology, Gifu University School of Medicine, Gifu City, Japan.
出版信息
Antimicrob Agents Chemother. 1998 Feb;42(2):433-5. doi: 10.1128/AAC.42.2.433.
Abstract
The gyrA and parC genes of 31 clinical isolates of Enterococcus faecalis, including fluoroquinolone-resistant isolates, were partially sequenced and analyzed for target alterations. Topoisomerase IV may be a primary target in E. faecalis, but high-level fluoroquinolone resistance was associated with simultaneous alterations in both GyrA and ParC.
摘要
对31株粪肠球菌临床分离株（包括耐氟喹诺酮类分离株）的gyrA和parC基因进行了部分测序，并分析了靶点改变情况。拓扑异构酶IV可能是粪肠球菌中的主要靶点，但高水平氟喹诺酮耐药性与GyrA和ParC同时发生改变有关。
相似文献
1
Alterations in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV associated with quinolone resistance in Enterococcus faecalis.粪肠球菌中与喹诺酮耐药性相关的DNA回旋酶GyrA亚基和DNA拓扑异构酶IV的ParC亚基的改变。
Antimicrob Agents Chemother. 1998 Feb;42(2):433-5. doi: 10.1128/AAC.42.2.433.
2
Alteration in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV in quinolone-resistant clinical isolates of Staphylococcus epidermidis.表皮葡萄球菌喹诺酮耐药临床分离株中DNA回旋酶的GyrA亚基和DNA拓扑异构酶IV的ParC亚基的改变。
Antimicrob Agents Chemother. 1998 Dec;42(12):3293-5. doi: 10.1128/AAC.42.12.3293.
3
Alterations in GyrA and ParC associated with fluoroquinolone resistance in Enterococcus faecium.粪肠球菌中与氟喹诺酮耐药性相关的GyrA和ParC改变。
Antimicrob Agents Chemother. 1999 Apr;43(4):947-9. doi: 10.1128/AAC.43.4.947.
4
In vitro selection of fluoroquinolone-resistant Neisseria gonorrhoeae harboring alterations in DNA gyrase and topoisomerase IV.体外筛选携带DNA促旋酶和拓扑异构酶IV改变的耐氟喹诺酮淋病奈瑟菌。
J Urol. 2000 Sep;164(3 Pt 1):847-51. doi: 10.1097/00005392-200009010-00060.
5
Alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV in quinolone-resistant clinical isolates of Klebsiella pneumoniae.肺炎克雷伯菌喹诺酮耐药临床分离株中DNA促旋酶的GyrA亚基和拓扑异构酶IV的ParC亚基的改变。
Antimicrob Agents Chemother. 1997 Mar;41(3):699-701. doi: 10.1128/AAC.41.3.699.
6
Quinolone-resistant Neisseria gonorrhoeae: correlation of alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV with antimicrobial susceptibility profiles.耐喹诺酮淋病奈瑟菌：DNA 回旋酶 GyrA 亚基和拓扑异构酶 IV 的 ParC 亚基改变与抗菌药物敏感性谱的相关性
Antimicrob Agents Chemother. 1996 Apr;40(4):1020-3. doi: 10.1128/AAC.40.4.1020.
7
Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV of Enterococcus faecalis.喹诺酮类药物对粪肠球菌DNA回旋酶和拓扑异构酶IV的抑制活性。
Antimicrob Agents Chemother. 2002 Jun;46(6):1800-4. doi: 10.1128/AAC.46.6.1800-1804.2002.
8
Detection of mutations in the gyrA and parC genes in quinolone-resistant clinical isolates of Enterobacter cloacae.阴沟肠杆菌喹诺酮耐药临床分离株中gyrA和parC基因突变的检测
J Antimicrob Chemother. 1997 Oct;40(4):543-9. doi: 10.1093/jac/40.4.543.
9
Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.金黄色葡萄球菌DNA拓扑异构酶IV的克隆及一级结构：氟喹诺酮类药物的主要作用靶点
Mol Microbiol. 1994 Aug;13(4):641-53. doi: 10.1111/j.1365-2958.1994.tb00458.x.
10
Analysis by PCR and direct DNA sequencing of gyrA mutations associated with fluoroquinolone resistance in Enterococcus faecalis.通过聚合酶链反应（PCR）及直接DNA测序对粪肠球菌中与氟喹诺酮耐药性相关的gyrA基因突变进行分析。
Antimicrob Agents Chemother. 1994 Sep;38(9):2091-4. doi: 10.1128/AAC.38.9.2091.
引用本文的文献
1
ESKAPE and Beyond: The Burden of Coinfections in the COVID-19 Pandemic.“ESKAPE” 及其以外：新冠疫情中的合并感染负担
Pathogens. 2023 May 22;12(5):743. doi: 10.3390/pathogens12050743.
2
Treatment of Infective Endocarditis: A Continuing Challenge.感染性心内膜炎的治疗：一项持续的挑战。
Antibiotics (Basel). 2023 Apr 4;12(4):704. doi: 10.3390/antibiotics12040704.
3
Vancomycin Resistance in and .[具体研究对象]中的万古霉素耐药性 以及[具体研究对象]。
你提供的原文信息不完整，我只能按照要求进行这样的翻译。请补充完整原文以便我能给出更准确的译文。
Microorganisms. 2022 Dec 21;11(1):24. doi: 10.3390/microorganisms11010024.
4
Virulence and Resistant Traits Associated with Its Permanence in the Hospital Environment.与其在医院环境中持续存在相关的毒力和耐药特性。
Antibiotics (Basel). 2022 Jun 26;11(7):857. doi: 10.3390/antibiotics11070857.
5
Bacterial Adaptation to Venom in Snakes and Arachnida.蛇和蛛形纲动物中细菌对毒液的适应性。
Microbiol Spectr. 2022 Jun 29;10(3):e0240821. doi: 10.1128/spectrum.02408-21. Epub 2022 May 23.
6
Co-Incidence of Type II Topoisomerase Mutations and Efflux Expression in High Fluoroquinolone Resistant Isolated from Urinary Tract Infections.从尿路感染分离出的高氟喹诺酮耐药菌株中II型拓扑异构酶突变与外排表达的共现情况
Infect Drug Resist. 2020 Feb 18;13:553-559. doi: 10.2147/IDR.S237299. eCollection 2020.
7
The Enterococcus: a Model of Adaptability to Its Environment.肠球菌：适应环境的典范。
Clin Microbiol Rev. 2019 Jan 30;32(2). doi: 10.1128/CMR.00058-18. Print 2019 Mar 20.
8
Draft Genome Sequence for a Clinical Isolate of Vancomycin-Resistant Enterococcus faecalis.耐万古霉素粪肠球菌临床分离株的基因组序列草图
Genome Announc. 2016 Jun 23;4(3):e00584-16. doi: 10.1128/genomeA.00584-16.
9
Antimicrobial Resistance and Molecular Investigation of H2S-Negative Salmonella enterica subsp. enterica serovar Choleraesuis Isolates in China.中国H2S阴性肠炎沙门氏菌猪霍乱血清型分离株的耐药性及分子研究
PLoS One. 2015 Oct 2;10(10):e0139115. doi: 10.1371/journal.pone.0139115. eCollection 2015.
10
Antimicrobial resistance in Salmonella enterica Serovar Typhi isolates from Bangladesh, Indonesia, Taiwan, and Vietnam.来自孟加拉国、印度尼西亚、台湾和越南的伤寒沙门氏菌血清型伤寒菌株中的抗菌药物耐药性。
Antimicrob Agents Chemother. 2014 Nov;58(11):6501-7. doi: 10.1128/AAC.03608-14. Epub 2014 Aug 18.
本文引用的文献
1
Apparent involvement of a multidrug transporter in the fluoroquinolone resistance of Streptococcus pneumoniae.多药转运蛋白明显参与肺炎链球菌对氟喹诺酮类药物的耐药性。
Antimicrob Agents Chemother. 1997 Jun;41(6):1396-8. doi: 10.1128/AAC.41.6.1396.
2
Characterization of a mutation in the parE gene that confers fluoroquinolone resistance in Streptococcus pneumoniae.肺炎链球菌中赋予氟喹诺酮耐药性的parE基因突变特征分析。
Antimicrob Agents Chemother. 1997 May;41(5):1166-7. doi: 10.1128/AAC.41.5.1166.
3
Alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV in quinolone-resistant clinical isolates of Klebsiella pneumoniae.肺炎克雷伯菌喹诺酮耐药临床分离株中DNA促旋酶的GyrA亚基和拓扑异构酶IV的ParC亚基的改变。
Antimicrob Agents Chemother. 1997 Mar;41(3):699-701. doi: 10.1128/AAC.41.3.699.
4
Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones.司帕沙星对肺炎链球菌中DNA回旋酶的靶向作用：喹诺酮类药物对回旋酶或拓扑异构酶IV的选择性靶向作用
Antimicrob Agents Chemother. 1997 Feb;41(2):471-4. doi: 10.1128/AAC.41.2.471.
5
Development of fluoroquinolone resistance in Enterococcus faecalis and role of mutations in the DNA gyrase gyrA gene.粪肠球菌中氟喹诺酮耐药性的产生及DNA回旋酶gyrA基因突变的作用。
Antimicrob Agents Chemother. 1996 Nov;40(11):2558-61. doi: 10.1128/AAC.40.11.2558.
6
Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro.gyrA和parC基因突变对体内外获得的肺炎链球菌突变体氟喹诺酮耐药性的影响。
Antimicrob Agents Chemother. 1996 Nov;40(11):2505-10. doi: 10.1128/AAC.40.11.2505.
7
Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae.拓扑异构酶IV和DNA促旋酶作为环丙沙星在肺炎链球菌中的作用靶点。
Antimicrob Agents Chemother. 1996 Oct;40(10):2321-6. doi: 10.1128/AAC.40.10.2321.
8
ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype.肺炎链球菌DNA拓扑异构酶IV的ParC亚基是氟喹诺酮类药物的主要作用靶点，并与DNA回旋酶A亚基协同形成耐药表型。
Antimicrob Agents Chemother. 1996 Oct;40(10):2252-7. doi: 10.1128/AAC.40.10.2252.
9
Quinolone-resistant mutants of escherichia coli DNA topoisomerase IV parC gene.大肠杆菌DNA拓扑异构酶IV parC基因的喹诺酮抗性突变体
Antimicrob Agents Chemother. 1996 Mar;40(3):710-14. doi: 10.1128/AAC.40.3.710.
10
Quinolone-resistant Neisseria gonorrhoeae: correlation of alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV with antimicrobial susceptibility profiles.耐喹诺酮淋病奈瑟菌：DNA 回旋酶 GyrA 亚基和拓扑异构酶 IV 的 ParC 亚基改变与抗菌药物敏感性谱的相关性
Antimicrob Agents Chemother. 1996 Apr;40(4):1020-3. doi: 10.1128/AAC.40.4.1020.
Zotero 插件